FibroBiologics (NASDAQ:FBLG) Given “Hold” Rating at D. Boral Capital

FibroBiologics (NASDAQ:FBLG)‘s stock had its “hold” rating reaffirmed by stock analysts at D. Boral Capital in a research note issued on Thursday,Benzinga reports.

A number of other brokerages have also recently issued reports on FBLG. Weiss Ratings reissued a “sell (e+)” rating on shares of FibroBiologics in a report on Thursday, January 22nd. HC Wainwright cut their price objective on shares of FibroBiologics to $4.00 and set a “buy” rating for the company in a research report on Thursday, February 26th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $5.50.

FibroBiologics Trading Down 16.9%

Shares of NASDAQ FBLG traded down $0.04 during midday trading on Thursday, hitting $0.22. The company’s stock had a trading volume of 2,103,080 shares, compared to its average volume of 1,313,633. The stock has a fifty day moving average price of $0.31 and a 200 day moving average price of $0.36. FibroBiologics has a one year low of $0.19 and a one year high of $1.53. The firm has a market capitalization of $14.80 million, a price-to-earnings ratio of -0.52 and a beta of -0.69.

FibroBiologics (NASDAQ:FBLG) last released its quarterly earnings data on Tuesday, February 24th. The company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.06. On average, equities research analysts predict that FibroBiologics will post -0.53 earnings per share for the current fiscal year.

Insider Buying and Selling at FibroBiologics

In other FibroBiologics news, CFO Jason Davis purchased 70,000 shares of the stock in a transaction on Monday, March 2nd. The shares were purchased at an average price of $0.41 per share, with a total value of $28,700.00. Following the acquisition, the chief financial officer directly owned 70,000 shares in the company, valued at approximately $28,700. The trade was a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last 90 days, insiders bought 191,500 shares of company stock valued at $72,893. Company insiders own 13.00% of the company’s stock.

Hedge Funds Weigh In On FibroBiologics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. AQR Capital Management LLC bought a new position in shares of FibroBiologics in the 1st quarter worth $29,000. XTX Topco Ltd grew its position in FibroBiologics by 160.0% in the second quarter. XTX Topco Ltd now owns 45,945 shares of the company’s stock worth $29,000 after acquiring an additional 28,276 shares in the last quarter. AMG National Trust Bank bought a new position in FibroBiologics in the fourth quarter valued at $31,000. Jane Street Group LLC bought a new position in FibroBiologics in the fourth quarter valued at $34,000. Finally, Marshall Wace LLP purchased a new stake in FibroBiologics during the second quarter valued at about $49,000.

About FibroBiologics

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc was incorporated in 2021 and is based in Houston, Texas.